MB04 (etanercept biosimilar)
/ Insud Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
October 01, 2025
MB04-A-01-23: A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders
(clinicaltrials.gov)
- P1 | N=141 | Completed | Sponsor: mAbxience Research S.L. | Active, not recruiting ➔ Completed | Trial primary completion date: Sep 2024 ➔ May 2025
Trial completion • Trial primary completion date • Immunology
May 12, 2025
MB04-A-01-23: A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders
(clinicaltrials.gov)
- P1 | N=132 | Active, not recruiting | Sponsor: mAbxience Research S.L. | Trial completion date: Dec 2024 ➔ May 2025
Trial completion date • Immunology
September 24, 2024
MB04-A-01-23: A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially Be Used in the Treatment of Autoimmune Disorders
(clinicaltrials.gov)
- P1 | N=132 | Active, not recruiting | Sponsor: mAbxience Research S.L. | Recruiting ➔ Active, not recruiting | Trial completion date: Sep 2024 ➔ Dec 2024
Enrollment closed • Trial completion date • Immunology
September 19, 2024
A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis
(clinicaltrials.gov)
- P3 | N=458 | Recruiting | Sponsor: mAbxience Research S.L.
New P3 trial • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology
April 30, 2024
MB04-A-01-23: A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders
(clinicaltrials.gov)
- P1 | N=132 | Recruiting | Sponsor: mAbxience Research S.L.
New P1 trial • Immunology
1 to 5
Of
5
Go to page
1